Mexidol® is a reference (original) preparation of ethylmethylhydroxypyridine succinate.

The 20th anniversary of administration of Mexidol® in clinical practice is in 2016. Mexidol® is the first preparation of ethylmethylhydroxypyridine succinate, included in the Order of the Ministry of Healthcare of the RF of December 31, 1996, No. 432 “On Permission for Medical Use”.

In accordance with Federal Law No. 61-FZ of April 12, 2010 “On Drug Circulation”, the preparation “Mexidol” (film-coated tablets, solution for intravenous and intramuscular injections) was recognized by FSBI (Federal State Budgetary Institution) “Scientific Center for Expertise of Medical Products” (“SCEMP”) of the Ministry of Healthcare of Russia as referent (i.e. original) preparation of ethylmethylhydroxypyridine succinate.

Mexidol® was synthesized in the early 1980s at State Institution Research Institute of Pharmacology of the RAMS (Russian Academy of Medical Sciences) under the supervision of Academician of RAMS A.V. Valdman by pharmacologists L.D. Smirnov and V.I. Kuzmin. In 2003, for development and introduction of Mexidol® into clinical practice, a group of specialists was awarded by the RF Government Prize “For Creation and Introduction into Clinical Practice of Antioxidant Drugs for Treatment & Prevention of Cerebrovascular Diseases” (RF Government Decree No. 112 of February 18, 2003 “On Awarding Prizes from Government of the Russian Federation in 2002 in Science & Technology”). Based on confirmed data on clinical effectiveness, since 2006, Mexidol® (GN ethylmethylhydroxypyridine succinate) is in the List of Vital & Essential Drugs (LVED). Mexidol® (GN ethylmethylhydroxypyridine succinate) is included in bag of emergency medical care, and in 39 the most important standards of care, among them the Standard for specialized care in brain infarction (ischemic stroke), including prehospital phase, the Standard of Specialized Medical Care in disorders of intervertebral disc and other parts of spine with radiculopathy and other most current standards, used in neurology, narcology, psychiatry, ophthalmology, etc.

In 2014, Mexidol® received the Russian Pharma Award in nomination “The drug of Choice in Treatment of Ischemic Disorders, Caused by Cerebral Vasospasm.” Over the years, clinical use of Mexidol® has been recognized by both medical community and patients, recovering the life energy after vascular catastrophes.